Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.13 USD
Change Today -0.003 / -2.26%
Volume 234.0K
HEB On Other Exchanges
As of 8:04 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One Penn Center

1617 JFK Boulevard

Suite 500

Philadelphia, PA 19103

United States

Phone: 215-988-0080

Fax: 215-988-1739

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. Products Ampligen: The company’s double-stranded RNA (ribonucleic acid) drug product, trademarked Ampligen, is an experimental, unapproved drug that would be administered intravenously. Ampligen is undergoing clinical development for the treatment of Chronic Fatigue Syndrome Treatment (CFS). Ampligen has received various designations, including Orphan Drug Product Designation (FDA), Treatment IND with Cost Recovery Authorization (FDA) and ‘promising’ clinical outcome recognition based on the evaluation of certain summary clinical reports (AHRQ or Agency for Healthcare Research and Quality). Ampligen represents the first drug in the class of large (macromolecular) RNA (nucleic acid) molecules to apply for New Drug Application (NDA) review. Alferon N Injection Alferon N Injection is the registered trademark for the injectable formulation of natural alpha interferon, which was approved by the FDA for the treatment of certain categories of genital warts. Alferon is the only natural-source, multi-species alpha interferon approved for sale in the U.S. for the intralesional (within lesions) treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Alferon N Injection contains a multi-species form of alpha interferon. The company’s natural alpha interferon is produced from human white blood cells. Alferon LDO (Low Dose Oral) Alferon LDO is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon. It is an experimental immunotherapeutic, which works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. The company has an FDA authorized protocol to conduct a Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon LDO for the prophylaxis and treatment of seasonal influenza of more than 200 subjects. Patents and Non-Patent Exclusivity Rights As of December 31, 2014, the company had 25 patents worldwide with 27 additional pending patent applications comprising its intellectual property. History Hemispherx Biopharma, Inc. was founded in 1990.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.13 USD -0.003

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $320.26 USD +8.83
AstraZeneca PLC 4,520 GBp +20.00
Baxter International Inc $37.88 USD -0.16
Medigene AG €5.84 EUR +0.247
Sarepta Therapeutics Inc $37.49 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 219.7x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 135.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at